In the current study, 43 pharmaceuticals and 18 transformation products were studied in the river Meuse at the Belgian-Dutch border and four tributaries of the river Meuse in the southern part of the Netherlands. The tributaries originate from Belgian, Dutch and mixed Dutch and Belgian catchments. In total, 23 pharmaceuticals and 13 transformation products were observed in samples of river water collected from these rivers. Observed summed concentrations of pharmaceuticals and transformation products in river water ranged from 3.5 to 37.8 μg/L. Metformin and its transformation product guanylurea contributed with 53 to 80 % to this concentration, illustrating its importance on a mass basis. Data on the flow rate of different rivers and demographics of the catchments enabled us to calculate daily per capita loads of pharmaceuticals and transformation products. These loads were linked to sales data of pharmaceuticals in the catchment. Simple mass balance modelling accounting for human excretion and removal by sewage treatment plants revealed that sales could predict actual loads within a factor of 3 for most pharmaceuticals. Rivers that originated from Belgian and mixed Dutch and Belgian catchments revealed significantly higher per capita loads of pharmaceuticals (16.0±2.3 and 15.7±2.1 mg/ inhabitant/day, respectively) than the Dutch catchment (8.7± 1.8 mg/inhabitant/day). Furthermore, the guanylurea/metformin ratio was significantly lower in waters originating from Belgium (and France) than in those from the Netherlands, illustrating that sewage treatment in the Belgian catchment is less efficient in transforming metformin into guanylurea. In summary, the current study shows that consumption-based modelling is suitable to predict environmental loads and concentrations. Furthermore, different consumption patterns and wastewater treatment efficiency are clearly reflected in the occurrence and loads of pharmaceuticals in regional rivers.
Introduction
Numerous studies describe the presence of pharmaceuticals in the aqueous environment (Monteiro and Boxall 2010; Roig 2010) . These pharmaceuticals can originate from human consumption, veterinary consumption, aquaculture or (accidental) emissions during production (Larsson et al. 2007 ) and transport of pharmaceuticals. Consumed human pharmaceuticals are excreted by humans via urine and faeces. They are subsequently transported to sewage treatment facilities and are (partially) emitted to surface waters. However, not all consumed pharmaceuticals end up in the environment since they can be metabolized in the human body. After excretion, pharmaceuticals and metabolites can be further transformed or sorbed in sewage systems, sewage
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Electronic supplementary material The online version of this article (doi:10.1007/s11356-014-3233-9) contains supplementary material, which is available to authorized users. treatment plants (active sludge) and receiving waters. The rates and nature of the metabolism, transformation and sorption depend on the chemical properties of the pharmaceutical, the physiology of the person using the medication, and environmental conditions in wastewater treatment and receiving waters. While parent pharmaceuticals have been studied intensively in the environment over the last decades, metabolites and transformation products (later all referred to as transformation products) have drawn less attention in monitoring and risk assessment (Escher and Fenner 2011) .
Databases on the sales of pharmaceuticals and extensive knowledge of excretion and metabolism, stability and sorption in commonly applied sewage treatment systems, and stability and sorption in receiving waters enable one to relate sales to loads in surface waters (Castiglioni et al. 2004; Liebig et al. 2006; Alder et al. 2010; ter Laak et al. 2010; Kugathas et al. 2012) . Furthermore, pharmaceutical consumption varies between regions (Van den Berg Jeths and Van Batenburg-Eddes 2003) and countries (Mossialos et al. 2004) , while sewage treatment practice and environmental conditions differ between regions, countries (Boyjoo et al. 2013 ) and seasons (Sui et al. 2011) . Regional consumption data and knowledge on sewage treatment practice can guide monitoring efforts in different regions, countries or seasons and define 'hot spots' where environmental risks are the highest. Furthermore, it can be applied to model regional emissions and predict emissions under different consumption, wastewater treatment and river discharge scenarios.
The assessment of water quality for the ecosystem health and for drinking water production can benefit from knowledge of regional sources, emissions and occurrence of pharmaceuticals. Additionally, it can benefit from knowledge on the formation and occurrence of transformation products. In the present work, three approaches are defined to gain knowledge and assess the fate and behaviour of pharmaceuticals and transformation products in the environment.
First, ratios of pharmaceuticals and transformation products were studied in order to reveal whether ratios between parent compounds and their products are stable and might allow prediction of one concentration from the other. Ratios between different pharmaceuticals were not studied, but this might be of interest in future research. Second, the occurrence of pharmaceuticals and transformation products was studied and linked to available sales data to reveal whether sales data are suitable to predict loads in regional surface waters. Finally, the composition of pharmaceuticals in different rivers fed by sewage from Belgium and the Netherlands was qualitatively and quantitatively evaluated to reveal differences between countries.
Material and method

Sampling locations
Samples were taken in the river Meuse catchment of the province of Limburg, the most southern province of the Netherlands (Fig. 1) . Water from the river Meuse was sampled near Eijsden where the river Meuse crosses the border between Belgium and the Netherlands. Four tributaries of the river Meuse, i.e. the river Jeker, the river Geul and the river Geleenbeek and river Slijbeek (later referred to as the Jeker, Geul, Geleenbeek and Slijbeek), were sampled near the point where they flow into the river Meuse or into a channel that is connected to the river Meuse (i.e. Slijbeek). Table 1 shows the median, minimum and maximum flow rates of the selected rivers. Furthermore, the number of sewage treatment plants discharging to the different waters and the number inhabitants of the catchments are listed. These data are used to predict loads of pharmaceuticals in the different waters and relate predicted loads to monitoring data.
Each of the five locations was sampled in 2011 on November 23, November 30, December 7 and December 12 between 9:00 and 13:00 by grab sampling. Water was collected in 1,000-mL ultra-clean dark green glass bottles and directly stored at 4°C for a maximum of 4 weeks. Further details can be found in Table S1 of Supplementary Information. Grab sampling was used because time-integrated sampling was not feasible at the sampling locations.
Pharmaceuticals and transformation products
Samples were analysed for 43 pharmaceuticals and 18 transformation products. The pharmaceuticals were selected based on consumption, occurrence in the environment, physicochemical properties, their availability as standards and whether they can be analysed (de Voogt et al. 2009 ). Pharmaceuticals and transformation products were obtained from Sigma-Aldrich, AK Scientific, Frinton Laboratories and CHEMOS. The purity of the chemicals was >97 %, except for clindamycin (88.3 %), erythromycin (95 %) and N-acetyl-4-aminoantipyrine (97 %). Deuterated (internal) standards (Atenolol-d7, Atrazine-d5, Bentazone-d6, Benzotriazool-d4, Carbamazepine-d10, Fluoxetine-d5, Gemfibrozil-d6, Metformin-d6, Paracetamol-d3, Phenazone-d3 and Sulfamethoxazole-d4) were obtained from CDN Isotopes. Detailed information on the pharmaceuticals studied is listed in Table S2 of the Supplementary Information.
Analysis of pharmaceuticals and transformation products in water Aqueous samples were filtered over a 0.20-μm regenerated cellulose filter (Whatman, Spartan 30/B). One hundred microlitres of the filtrated water samples (spiked with 0.5 μg/L internal standards) was directly injected on a Thermo Scientific TSQ Vantage liquid chromatography (LC)-MS/MS equipped with an Accela autosampler and pump. The LC system was equipped with either a reversed phase column, i.e. a 100×2.1-mm Hypersil Gold column with a particle size of 1.9 μm (Thermo Scientific), or with a ZIC-HILIC column, i.e. a 100×2.1-mm ZIC-HILIC column with 3.5-μm particle size. The temperature of the columns was held constant at 25°C. An ESI interface was used to ionize the compounds, and analysis was performed both in positive and negative ionization modes. All pharmaceuticals were analysed using reversed phase chromatography, except for metformin and guanylurea which were analysed using the HILIC column. Details on LC conditions and gradients are listed in the "Description of chemical analysis" of the Supplementary Information. The ratio of the responses of at least two mass transitions was used for positive identification of the individual compounds. The average response of these two masses was used for quantification and comparison with external calibration standards (Mezcua et al. 2009 ). All analyses were performed within one analytical run, and blanks and external standards were added every ten samples to monitor analytical performance.
Limits of quantification were generally 0.01 μg/L, except for 4-acetaminophen sulphate, cortisol, cortisone and erythromicine A (all 0.025 μg/L), O-desmethyl naproxen, paroxetine, prednisolone, metformin and guanylurea (all 0.050 μg/L), norfluoxetine, hydroxy ibuprofen and ciprofloxacin (all 0.50 μg/L) and salicylic acid (>5.0 μg/L). No corrections were made for recoveries as most recoveries of detected compounds were between 80 and 120 %. Details can be found in Table S2 of the Supplementary Information. Calculating emissions from monitoring data Flow rate data with a 15-min (Jeker, Geul, Geleenbeek) or 10 h (Meuse) interval were obtained from regional water authorities. Flow rates showed some scatter in time; therefore, the total water flow over a period of 24 h (Q day ) at the sampling date was multiplied with the observed concentration of the pharmaceutical or transformation product (TP) (C pharmaceutical ) to calculate the daily load (Q day ):
Furthermore, loads per inhabitant (Q inhab ) were calculated to compare emissions of inhabitants from different regions according to
For the Slijbeek, no flow rate data were available, so loads could not be calculated.
Predicting emissions from sales data
Sales data of pharmaceuticals in 2011 were obtained from the Dutch Foundation for Pharmaceutical Statistics (SFK) and the Belgian National Institute for Disease and Disability Insurance (RIZIV). It was assumed that the consumption of the inhabitants of the Geleenbeek and Geul catchment corresponded to the Dutch and combined Dutch and Belgian national average, respectively. This assumption seems valid since the sales of pharmaceuticals in the region that covers the Geleenbeek basin and the Dutch part of the Geul basin is near 100 % (106 %) of the Dutch average (van Batenburg-Eddes et al. 2002) . For the Jeker catchment, regional sales data of 91,645 out of the 101,535 (Directorate General Statistics and Economic Information 2013) inhabitants in 2011 were obtained. Here, it was assumed that the consumption of the 10 % missing inhabitants was the same as for inhabitants of which sales data were obtained.
Finally, for all catchments, it was assumed that all residents of the catchment discharge all their sewage via sewage treatment plants in their catchment of residence. This assumption might not always be correct since commuting, travelling (holidays) the use of septic tanks and emissions of untreated sewage can bias the actual discharge. There are, however, no suitable data to correct for these biases.
Daily emitted loads (Q day-pred ) were estimated using respective annual sales data (Q year ) of 2011, the fraction that passes the sewage treatment plant (f STP ) and the excretion rate 
The sewage treatment plant (STP) removal rates and human excretion rates are listed in Table 2 , and the Dutch and Belgian Q year values are listed in Table S3 of the Supplementary Information. Generic removal rates are used to predict emissions since there were no regional STP-specific removal rates available. It should be noted that the number of inhabitants in the Jeker catchment exceeded the inhabitant equivalents of the STPs due to insufficient capacity of the some treatment plants and the fact that not all wastewater is treated in STPs (SPGE 2006) . So, the applied generic removal rates in Table 2 might overestimate actual removal of some pharmaceuticals for the Jeker catchment.
Results and discussion
Analytical results
Twenty-four pharmaceuticals and 13 transformation products were observed in the surface waters. Figure 2 shows the concentration ranges of the pharmaceuticals observed and the percentage of positive detections (%) in all samples.
The transformation product guanylurea and its parent pharmaceutical metformin show the highest concentrations in surface waters. Furthermore, high concentrations of transformation products such as hydroxy ibuprofen, transdiol carbamazepine, acetaminophen sulphate and desmethyl tramadol are observed. These data show that transformation products can form a relevant proportion of the total pharmaceutical load of surface waters.
Grab sampling
Grab sampling during late autumn might not provide a representative 'average' sample since the emissions of STP show both daily and seasonal fluctuations in pharmaceutical emissions that are related to variations in consumption and treatment performance (ter Laak et al. 2010) . The daily variations in pharmaceutical emissions in the Geul and Geleenbeek are likely of minor impact since samples were taken 25 to 34 km downstream of the STP effluents, which is roughly equivalent to 0.5-to 1.0-day residence time (Personal Communication, Harry Tolkamp, Roer and Overmaas Regional Water Authority). The length of the Jeker is 65 km and there are 20 STPs with a total capacity of just over 100,000 inhabitant equivalents along its catchment. Additionally, ten STPs with a total capacity of approximately 35.000 to 40.000 I.E. are planned since various communities are not yet connected to sewage treatment and currently emit untreated wastewater into the Jeker (SPGE 2006) . Hence, for the Geleenbeek, Geul and (Carr et al. 1992) c (Lienert et al. 2007) d (Ardakani and Rouini 2009) e (Prescott 1980) f (Howell et al. 1993) g (European Medicines Agency 1998) h (Lamp et al. 1999) i (Vergouwen et al. 2011) j (Wick et al. 2009) k (Castiglioni et al. 2006) l No data found m (Radjenovic et al. 2007) n (Rúa-Gómez and Püttmann 2012) o (Radjenovic et al. 2007) p (Miege et al. 2009) q (Watkinson et al. 2007) r (Rosal et al. 2010) s (European Agency for the Evaluation of Medicinal Products 1997) t (Grubb et al. 1999) Jeker, sufficient mixing of the flow rates with relatively pristine river water had occurred before the actual sampling was performed. Contrastingly, the Slijbeek is fed by a single STP located only a few kilometres upstream from the sampling location. This sample can therefore be strongly influenced by daily fluctuations of concentrations of pharmaceuticals, so these data should be interpreted with care.
Pharmaceuticals and transformation products in surface waters Figure 3 shows the ratios of the concentrations of the transformation products (TPs) versus its parent pharmaceutical (PP) on a molar basis for the different rivers. The data of the Geul catchment (n=4) are excluded from the data shown in Fig. 3 as concentrations of pharmaceuticals and/or transformation products were often close to limits of quantification, revealing less accurate ratios than for the other sampling locations. Constant ratios enable to estimate concentrations of transformation products from the concentration of the parent molecule or vice versa. Metformin is excreted unchanged by humans (Van Loenen 2008) . Guanylurea is formed during sewage treatment (Scheurer et al. 2009 (Scheurer et al. , 2012 Oosterhuis et al. 2013) . Likely, similar processes occur in surface waters. However, there are no studies that have illustrated and quantified metformin breakdown rates in the aqueous environment. There is only sparse circumstantial evidence that suggests that rates in the environment are much lower than in STPs (Oosterhuis et al. 2013) . Additional information on environmental degradation of this compound is required to improve predictions on its environmental fate.
A study of eight Dutch sewage treatment plants revealed that 53 to 98 % of metformin is removed during treatment (Vergouwen et al. 2011) . Furthermore, Oosterhuis et al. (2013) reported up to 99 % metformin removal by secondary treatment with a membrane bioreactor and that 91 and 85 % of the metformin in the influent was recovered as guanylurea in the STP effluent and receiving water, respectively. The current data show a large variation in the ratio of metformin and guanylurea in surface waters. The average TP/PP ratio for these compounds is 8.7 with a 95 % confidence interval of 1.2 to 16.4 (n=16). Large differences are observed between and within rivers (Fig. 3) . The TP/PP ratio in the Slijbeek that is fed by a single Dutch STP varied from 3.4 to 40.1. Similar observations were made in the Geleenbeek that is fed by three Dutch STPs. The samples taken from the river Meuse at Eijsen (Belgian-Dutch border) and Jeker that are fed by Belgian sewage effluents show much lower TP/PP ratios of 0.55±0.28.
For both the Geleenbeek and Slijbeek, a clear difference in TP/PP ratio of metformin and guanylurea between the end of dry period (first two samples) and wet period (last two samples) was observed. In the dry period, the average TP/PP ratio was 30.1 with a standard deviation of ±14.8 (n=4), and in the wet period, a significantly lower TP/PP ratio of 3.7 with a standard deviation of ±2.5 (n=4) was observed (t test, p value 0.013). The river Meuse and Jeker samples also show significantly different ratios during dry and wet conditions as well (0.77±0.20 and 0.33±0.11 respectively, t test, p value 0.007). Possibly, rainfall events that increase flow of wastewater and reduce hydraulic retention times in treatment plants, and slightly lower temperatures during the last two sampling dates (surface water temperature 7.6 to 8.7°C vs. 8.3 to 10.1°C) affected the metformin transformation into guanylurea. This illustrates that the removal of metformin and the formation of guanylurea vary between rivers (or STPs) and with environmental conditions. The limited number of samples and variable ratios does not allow for a reliable estimation of concentrations of the transformation products from analysis of the parent molecule.
For carbamazepine, four human metabolites were observed in the surface waters. Interestingly, the molar ratios of the TPs and PP are similar within and between different surface waters (Fig. 3) . The TP/PP ratio of 10,11-trandiol carbamazepine is 2.7 with a narrow 95 % confidence interval (CI) of 2.6 to 2.9 (n = 15). The average TP/PP ratios of the 3-hydroxy carbamazepine, 2-hydroxy carbamazepine and epoxy carbamazepine are 0.20 (95 % CI 0.18 to 0.22, n =15), 0.17 (95 % CI 0.15 to 0.18, n=15) and 0.12 (95 % CI 0.11 to 0.13, n=15), respectively. Figure 4 illustrates the fraction of the consumed carbamazepine that can be retrieved as parent pharmaceutical and the abovementioned transformation products in the surface water of two catchments.
Fractions of carbamazepine and transformation products recovered in surface waters appear to be slightly lower but show a strikingly similar pattern to the fractions of these metabolites excreted in urine (Eichelbaum et al. 1985) . The excretion of 10,11-transdiol carbamazepine in mono-therapy and therapy combined with other anticonvulsants ranges from 26.5 to 49.9 % of the consumed amount. In this study, 20.2 to 31.5 % of the consumed carbamazepine could be recovered as 10,11-transdiol carbamazepine in surface waters. The excretion of 3-hydroxy carbamazepine in urine is 3.0 to 4.2 %, while 1.6 to 2.0 % was recovered surface waters in this study. For 2-hydroxy carbamazepine, these values amounted to 2.4 to 3.1 % versus 1.2 to 2.0 %, and for epoxy carbamazepine, 1.1 to 1.5 % versus 0.8 to 1.3 %.
Renal excretion rates of carbamazepine and its transformation products are well studied (Eichelbaum et al. 1985) , but the composition of the fraction that is excreted via faeces is (to our knowledge) unknown. In this study, 6.3 to 10.3 % of the consumed carbamazepine amount is recovered in receiving surface waters. The recalcitrance of carbamazepine in the sewage treatment and environment (Heberer 2002 ) and the stable ratios of the various transformation products that largely correspond to renal excretion suggest that the metabolites are also recalcitrant in sewage treatment and the environment. These constant ratios allow for highly accurate estimation of concentrations of the transformation products from analysis of the carbamazepine and vice versa.
The ratio of tramadol and the human metabolite Odesmethyl tramadol observed in surface waters in the present study is constant. The average TP/PP ratio for these compounds is 0.55 with a 95 % confidence interval of 0.49 to 0.62 (n=14). This is very similar to ratios observed in surface waters of earlier studies (de Jongh et al. 2012 ) and falls within ratios observed in human urine that range from 0.26 to 0.75 (Lintz et al. 1981; Ardakani and Rouini 2009; Chitil et al. 2009 ). Apparently, both tramadol and O-desmethyl tramadol are rather recalcitrant and stable ratio is retained in the urban water cycle. This stable ratio enables one to accurately estimate concentrations of O-desmethyl tramadol from analysis of tramadol and vice versa.
The average TP/PP ratio of α-hydroxymetoprolol is 0.15 with a 95 % confidence interval of 0.11 to 0.20 (n=11). This ratio is slightly lower than the observed metabolic ratio of 3.1 ±2.5 that equals a TP/PP ratio of 0.32 (Tu and Zhao 1995) . Minor differences might be explained by either higher removal of α-hydroxymetoprolol during sewage treatment or additional metoprolol excretion via faeces that was not accounted for in the cited study. The average TP/PP of sulfamethoxazole and its product N4-acetyl sulfamethoxazole observed amounts to 0.66 with a 95 % confidence interval of 0.42 to 0.89 (n= 15). This TP/PP is one fifth of the reported human excretion ratio of 3.15 (Lienert et al. 2007 ). Possibly, the acetylated sulfamethoxazole is partially removed or transformed during sewage treatment processes and in surface water. Partial removal or transformation during sewage treatment (Verlicchi et al. 2012 ) might explain why the TP/PP of metoprolol and sulfamethoxazole and their respective human metabolites show more variation than carbamazepine and tramadol. Unfortunately, there are, to our knowledge, no literature data on STP removal rates of the metabolites to verify this hypothesis. Nevertheless, the TP/PP of sulfamethoxazole and metoprolol appears rather stable and allows to estimate concentrations of the transformation products from analysis of the parent molecule and vice versa within a factor of 2.
Apparently, the average metabolism of pharmaceuticals by a large population of humans is stable while transformation and sorption processes further down the urban water cycle result in more variable removal rates for some pharmaceuticals. Considering this observation, it is relevant to investigate temperature, oxygen concentration, combination of oxic and anoxic conditions, redox potential, residence time in various treatment processes, composition of the water, applied treatment techniques, composition of biodegraders in active sludge, and adsorption processes on the removal of pharmaceuticals during sewage treatment (Onesios et al. 2009; Pomiès et al. 2013) . The TP/PP ratio might be a suitable parameter to monitor such processes and reveal parameters that affect transformation rates. Finally, the potential risks of both parent pharmaceuticals and transformation products need to be assessed for a proper environmental risk assessment. Loads of pharmaceuticals and transformation products
Loads were calculated for all pharmaceuticals and transformation products that were observed during all four sampling dates. The loads are predicted by multiplying the consumed pharmaceuticals by the predicted fraction excreted by the user and the fraction remaining during STP passage (Eq. 3 and Table 2 ), as discussed in the "Calculating emissions from monitoring data" section above. Figure 5a -c shows the observed daily loads of pharmaceuticals versus the predicted loads. Not all observed pharmaceuticals listed in Fig. 2 were included since, for some of these, either Dutch or Belgian sales data were lacking. Figure 5a -c shows that for some pharmaceuticals, the measured loads exceed predicted loads at one or more locations. The largest of these underestimations are observed for the analgesic/anti-inflammatory pharmaceuticals naproxen, ketoprofen and paracetamol. These underestimations are likely explained by additional 'over the counter' sales that are not registered by the Belgian and Dutch monitoring organizations since they are not only sold and documented by official pharmacies nor reimbursed by health insurance. Furthermore, the actual load of the lipid regulator gemfibrozil is underestimated by a factor of 3 in both the Geleenbeek and Geul. There is no obvious explanation for this underestimation. Gemfibrozil is, however, known to be excreted in conjugated forms (Dix et al. 1999) . Potentially, these conjugates are de-conjugated during sewage treatment and in the environment, resulting in higher loads of the parent pharmaceutical in receiving waters. Finally, lincomycin, a lincosamide antibiotic, shows a higher concentration in the Jeker than predicted from human consumption. Lincomycin is also used in veterinary practice, so emissions from veterinary use in the Jeker catchment potentially resulted in additional loads in the river.
Carbamazepine and three antibiotics (sulfamethoxazole, erythromycin A and metronidazole) show a twofold to fourfold lower concentration than predicted from sales. The overestimation of the concentrations of the antibiotics might be related to uncertainties in the reported removal rates by sewage treatment or metabolism, since the removal in these processes is both relevant ( Table 2 ). The consistent factor overestimation of carbamazepine concentrations cannot be explained by uncertainties in reported removal rates because carbamazepine is very persistent in sewage treatment and the environment (Clara et al. 2004 ). Oosterhuis monitored carbamazepine concentrations in sewage influent, effluent and receiving surface waters and compared these to their local sales data. A similar overestimation was observed in this study (Oosterhuis et al. 2013 ). The predicted environmental loads calculated in both studies are based upon excretion rates obtained from Lienert et al (Lienert et al. 2007 ). Lienert justly discusses the relevance of faecal excretion of carbamazepine for emissions into the environment, a factor that is often neglected in pharmacological studies. There is, however, no data supporting the assumption that solely the parent pharmaceutical is excreted via feces. The observed loads in the surface waters and ratio with transformation products in the present study suggest that the total excretion of non-metabolized carbamazepine is rather around 10 % than the 26 % proposed by Lienert et al. or the 1 to 3 % found in urine (Lienert et al. 2007) . However, additional studies are required to test this hypothesis.
In this study, the discrepancies between observed and predicted loads are a result of analytical uncertainties (small), uncertainties introduced by grab sampling (variable, depends on sampling location and sampling date and time), regional variation in consumption (generally small within countries, larger between countries), seasonal variations in consumption (relevant for some pharmaceuticals), uncertainties in sales data (relevant for some pharmaceuticals), transformation and excretion rates (relevant for some pharmaceuticals) variations in removal efficiencies of sewage treatment (can strongly vary within and between treatment plants). Discrepancies in the order of a factor of 3 are therefore likely to be observed (Alder et al. 2010; ter Laak et al. 2010) . Local data on consumption, excretion and treatment specific removal rates as well as improved sampling during different seasons can increase the accuracy of the prediction to some extent, but a certain degree of uncertainty will remain.
Per capita emission of pharmaceuticals and transformation products
The loads of the pharmaceuticals and transformation products present in all datasets are normalized per inhabitant and presented in Fig. 6 . The data illustrate that the per capita load of pharmaceuticals is higher for the Geul and Jeker compared to the that for Geleenbeek catchment. The per capita loads of the Slijbeek were not calculated since there were no flow rate data available. The loads in the river Meuse were not calculated because loads cannot be directly linked to sales, since this is a complex water system with variable flow rates between the river Meuse and various canals that are fed by the river Meuse and circumvent the sampling location at the Belgian-Dutch border.
Comparing per capita emissions from Belgium and the Netherlands
The Geul and Jeker showed a significantly higher per capita load of pharmaceuticals and transformation products than Geleenbeek (Fig. 6) . The Geul and Jeker (also) transport effluents from Belgian origin. This suggests that more pharmaceuticals are used in Belgium and/or that removal by sewage treatment in the Belgian part of the catchment is less efficient or not present (SPGE 2006) . The Geleenbeek and Jeker were selected for a more detailed comparison, since the Geul is fed by both Dutch and Belgian sewage effluents which might result in ambiguous data.
In Fig. 7 , per capita loads of the Belgian (Jeker) and Dutch (Geleenbeek) populations are plotted against each other. Since most of the data points in Fig. 7 are situated at the right hand side of the 1:1 line (diagonal in Fig. 7) , most pharmaceuticals and transformation products show a higher per capita load from the Belgian population. This corresponds to higher total per capita loads shown in Fig. 6 . Only a few pharmaceuticals and transformation products show higher per capita loads from the Dutch population. Part of the differences in per capita loads can be explained by differences in pharmaceutical consumption in Belgium and the Netherlands. For example, Dutch per capita sales of metoprolol are eight times higher than Belgian sales (SFK and RIZIV). This is reflected in the higher per capita load of both metoprolol and α-hydroxymetoprolol in the Geleenbeek. Furthermore, the twofold higher per capita load of furosemide in the Geleenbeek compared to the Jeker also corresponds to differences in sales in the Netherlands and Belgium (SFK and RIZIV). Finally, the absence of the lipid regulator gemfibrozil in waters originating from Belgium (Meuse and Jeker) can be explained by the fact that it is not prescribed and r e i m b u r s e d i n B e l g i u m ( B e l g i a n C e n t r e f o r Farmacotherapeutic Information (CFI) 2014).
On the other hand, the per capita loads of metformin, tramadol and its de-methylated transformation product, venlafaxine, naproxen, paracetamol, propranolol, ketoprofen and metronidazole exceed the Dutch per capita load over a factor of 3. For propranolol, tramadol and venlafaxine, the higher per capita loads can be explained by higher consumption in Belgium. Contrastingly, the consumption of metformin is very similar in both countries (SFK and RIZIV). Probably, the higher per capita load of metformin is explained by absence of or less efficient treatment of part of the Belgian sewage. This hypothesis is supported by the lower formation of guanylurea/metformin ratio in waters from Belgium (see "Pharmaceuticals and transformation products in surface waters" section). The higher per capita loads for the analgesics and anti-inflammatory pharmaceuticals ketoprofen, naproxen, paracetamol and ibuprofen (hydroxy ibuprofen is detected) are more difficult to explain from sales data since part of these pharmaceuticals are sold 'over the counter' without being registered.
Implications
The current study illustrates that there are regional differences in pharmaceutical loads and that concentrations in different catchments can be related to differences in sales patterns and absence of sewage treatment. A better understanding of the relation between consumption, excretion processes and removal or transformation efficiencies of STPs, emissions and further dilution, sorption and transformation in rivers and river systems enables to optimize use of (limited) monitoring activities. For example, relations between the occurrence of pharmaceuticals and transformation products and potentially even between different pharmaceuticals or between sales data and occurrence data can extend the application of monitoring data. Furthermore, knowledge on transformation processes and transformation products generated in sewage treatment also enables one to monitor and potentially interpret sewage treatment efficiency and further transformation in surface waters. 
